版本:
中国

BRIEF-Teva and Active Biotech announce CONCERTO trial of Laquinimod in RRMS did not meet primary endpoint

May 5 Teva Pharmaceutical Industries Ltd :

* Teva and Active Biotech announce CONCERTO trial of Laquinimod in RRMS did not meet primary endpoint

* Study shows secondary endpoint which measured change in brain volume compared to baseline was positive

* In study, secondary endpoints measuring time to confirmed disability progression at 6, 9 months did not reach significance

* "While we have no current plans to further pursue Laquinimod in RRMS, we are continuing to study it in two other trials"

* Teva continues to evaluate potential of Laquinimod in Primary Progressive MS and Huntington Disease Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐